Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Hospira Healthcare India Pvt. Ltd.
WARNING LETTER
•Hospira Healthcare India Pvt. Ltd.•April 3, 2018

Hospira Healthcare India Pvt. Ltd. – FDA Warning Letter, Apr 3, 2018

Record Details

The FDA issued a Warning Letter to Hospira Healthcare India Pvt. Ltd. following an inspection from March 27 to April 3, 2018, citing significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, rendering their drug products adulterated.

Key violations include: 1. **Incomplete Laboratory Records (21 CFR 211.194(a)):** The microbiology laboratory inaccurately reported test results, with analysts recording "Nil" for plates showing microbial growth. This compromised sterility assurance and raised concerns about the validity of all quality control laboratory results. 2. **Inadequate Investigation of Discrepancies (21 CFR 211.192):** The firm failed to thoroughly investigate recurring critical defects and poor control in their manufacturing process, specifically regarding excessive critical defect rates in batches and issues with the manufacturing process leading to quality attribute specification failures. 3. **Failure to Conform to Final Specifications (21 CFR 211.165(a)):** Drug product batches were released without appropriate laboratory determination of satisfactory conformance to final specifications. Retesting of previously "passing" batches under FDA observation yielded Out-of-Specification (OOS) results, indicating data integrity issues related to testing procedures.

The FDA noted the firm's decision to suspend drug product release and recall affected batches. The Warning Letter emphasizes the need for a comprehensive investigation into the extent of data

Company
Hospira Healthcare India Pvt. Ltd.
Inspection date
April 3, 2018
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Rafael E. Arroyo (Senior Policy Advisor)
View Company Profile

ID · f02abefc-9a00-44e8-91f7-319d6970f584

Violation Codes9
21 CFR 21021 CFR 21121 CFR 211.194(a)21 CFR 211.19221 CFR 211.165(a)FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Hospira Healthcare India Pvt. Ltd.
  • WARNING_LETTER - 2012-10-10October 10, 2012

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hospira Healthcare India Pvt. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.